The agreements covers Zealand's drug, petrelintide, which works by mimicking the amylin hormone. Amylin is co-secreted with insulin. In theory, these drugs could preserve lean muscle mass better ...

The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of amylin, a hormone in the body that plays a role in regulating blood sugar and appetite. Activating ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Amylin is a hormone that gives a feeling of fullness in the brain that suppresses appetite, reduces food intake, and delays gastric emptying. In a six-week, phase 1 study reported last year ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

a synthetic version of the hormone amylin, which is released by the pancreas. Cagrilintide is currently being developed in combination with semaglutide to see if it helps overweight and obese ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Since the announcement in early March, AbbVie stock reached an all-time high at over $216 per share. The stock has fallen ...

Petrelintide belongs to a class of drugs known as long-acting amylin analogues, which mimic a hormone called amylin that is co-secreted with insulin. The first wave of obesity drugs was based ...

Both Ozempic and Zepbound target the GLP-1 hormone. By contrast, GUBamy acts as an analog of the body’s amylin hormone. Amylin has been identified as a potential therapeutic target for obesity ...